The board of directors of SSY Group Limited announced that the Group's Benserazide hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Berazide hydrochloride is a decarboxylase inhibitor, which is mainly used in combination with Levodopa for the treatment of Parkinson's disease.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.78 HKD | +0.21% | +1.92% | -3.24% |
Apr. 23 | SSY Group Get Production, Registration Approval for Pneumonia Drug from Chinese Regulator | MT |
Apr. 16 | SSY Group Logs Nearly 15% Boost in Q1 Profit | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.24% | 1.81B | |
+26.47% | 664B | |
+24.95% | 567B | |
-6.33% | 354B | |
+19.35% | 330B | |
+4.23% | 286B | |
+14.28% | 234B | |
+4.62% | 199B | |
-9.73% | 196B | |
-4.04% | 148B |
- Stock Market
- Equities
- 2005 Stock
- News SSY Group Limited
- SSY Group Limited Announces Update on Product Development